APO Research
Talk to an analyst

APO RESEARCH · REPORT

Plasma Protein Therapeutics

Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

Selected research

Market Outlook & Growth Opportunities

Global Plasma Protein Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchPlasma Protein Therapeutics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Plasma Protein Therapeutics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Plasma Protein Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plasma Protein Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Plasma Protein Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.

Shire (Baxalta), CSL and Grifolsare the leaders of the Plasma Protein Therapeutics industry, which take about 55% market share. China is the major region of the global market, which takes about 45% market share.

This report provides an overview of the global Plasma Protein Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Plasma Protein Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Plasma Protein Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Plasma Protein Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Plasma Protein Therapeutics Segment by Company

Shire (Baxalta)

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

RAAS

CBPO

Hualan Bio

Kamada

Plasma Protein Therapeutics Segment by Type

Coagulation Factor

Immune Globulin

Albumin

Others

Plasma Protein Therapeutics Segment by Application

Hemophilia

PID

Others

Plasma Protein Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Plasma Protein Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Plasma Protein Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Plasma Protein Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Plasma Protein Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Protein Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plasma Protein Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Protein Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Plasma Protein Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Protein Therapeutics industry.

Chapter 3: Detailed analysis of Plasma Protein Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Plasma Protein Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Plasma Protein Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Plasma Protein Therapeutics Industry Trends Table 2. Plasma Protein Therapeutics Industry Drivers Table 3. Plasma Protein Therapeutics Industry Opportunities and Challenges Table 4. Plasma Protein Therapeutics Industry Restraints Table 5. Global Plasma Protein Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Plasma Protein Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Plasma Protein Therapeutics Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Plasma Protein Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Plasma Protein Therapeutics Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Plasma Protein Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Plasma Protein Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Plasma Protein Therapeutics Company, Product Type & Application Table 13. Global Plasma Protein Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Plasma Protein Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Coagulation Factor Table 18. Significant Companies of Immune Globulin Table 19. Significant Companies of Albumin Table 20. Significant Companies of Others Table 21. Global Plasma Protein Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Plasma Protein Therapeutics Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Plasma Protein Therapeutics Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Plasma Protein Therapeutics Sales Volume Share by Type (2021-2026) Table 25. Global Plasma Protein Therapeutics Sales Volume Share by Type (2027-2032) Table 26. Global Plasma Protein Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Plasma Protein Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Plasma Protein Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Plasma Protein Therapeutics Sales Value Share by Type (2021-2026) Table 30. Global Plasma Protein Therapeutics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hemophilia Table 32. Significant Companies of PID Table 33. Significant Companies of Others Table 34. Global Plasma Protein Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Plasma Protein Therapeutics Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Plasma Protein Therapeutics Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Plasma Protein Therapeutics Sales Volume Share by Application (2021-2026) Table 38. Global Plasma Protein Therapeutics Sales Volume Share by Application (2027-2032) Table 39. Global Plasma Protein Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Plasma Protein Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Plasma Protein Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Plasma Protein Therapeutics Sales Value Share by Application (2021-2026) Table 43. Global Plasma Protein Therapeutics Sales Value Share by Application (2027-2032) Table 44. Global Plasma Protein Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Plasma Protein Therapeutics Sales by Region (2021-2026) & (K Units) Table 46. Global Plasma Protein Therapeutics Sales Market Share by Region (2021-2026) Table 47. Global Plasma Protein Therapeutics Sales by Region (2027-2032) & (K Units) Table 48. Global Plasma Protein Therapeutics Sales Market Share by Region (2027-2032) Table 49. Global Plasma Protein Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Plasma Protein Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Plasma Protein Therapeutics Sales Value Share by Region (2021-2026) Table 52. Global Plasma Protein Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Plasma Protein Therapeutics Sales Value Share by Region (2027-2032) Table 54. Global Plasma Protein Therapeutics Market Average Price (USD/Unit) by Region (2021-2026) Table 55. Global Plasma Protein Therapeutics Market Average Price (USD/Unit) by Region (2027-2032) Table 56. Global Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Plasma Protein Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Plasma Protein Therapeutics Sales by Country (2021-2026) & (K Units) Table 59. Global Plasma Protein Therapeutics Sales Market Share by Country (2021-2026) Table 60. Global Plasma Protein Therapeutics Sales by Country (2027-2032) & (K Units) Table 61. Global Plasma Protein Therapeutics Sales Market Share by Country (2027-2032) Table 62. Global Plasma Protein Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Plasma Protein Therapeutics Sales Value Market Share by Country (2021-2026) Table 64. Global Plasma Protein Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Plasma Protein Therapeutics Sales Value Market Share by Country (2027-2032) Table 66. Shire (Baxalta) Company Information Table 67. Shire (Baxalta) Business Overview Table 68. Shire (Baxalta) Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 69. Shire (Baxalta) Plasma Protein Therapeutics Product Portfolio Table 70. Shire (Baxalta) Recent Development Table 71. CSL Company Information Table 72. CSL Business Overview Table 73. CSL Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. CSL Plasma Protein Therapeutics Product Portfolio Table 75. CSL Recent Development Table 76. Grifols Company Information Table 77. Grifols Business Overview Table 78. Grifols Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Grifols Plasma Protein Therapeutics Product Portfolio Table 80. Grifols Recent Development Table 81. Octapharma Company Information Table 82. Octapharma Business Overview Table 83. Octapharma Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Octapharma Plasma Protein Therapeutics Product Portfolio Table 85. Octapharma Recent Development Table 86. Kedrion Company Information Table 87. Kedrion Business Overview Table 88. Kedrion Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Kedrion Plasma Protein Therapeutics Product Portfolio Table 90. Kedrion Recent Development Table 91. LFB Group Company Information Table 92. LFB Group Business Overview Table 93. LFB Group Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. LFB Group Plasma Protein Therapeutics Product Portfolio Table 95. LFB Group Recent Development Table 96. Biotest Company Information Table 97. Biotest Business Overview Table 98. Biotest Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Biotest Plasma Protein Therapeutics Product Portfolio Table 100. Biotest Recent Development Table 101. BPL Company Information Table 102. BPL Business Overview Table 103. BPL Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. BPL Plasma Protein Therapeutics Product Portfolio Table 105. BPL Recent Development Table 106. RAAS Company Information Table 107. RAAS Business Overview Table 108. RAAS Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. RAAS Plasma Protein Therapeutics Product Portfolio Table 110. RAAS Recent Development Table 111. CBPO Company Information Table 112. CBPO Business Overview Table 113. CBPO Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. CBPO Plasma Protein Therapeutics Product Portfolio Table 115. CBPO Recent Development Table 116. Hualan Bio Company Information Table 117. Hualan Bio Business Overview Table 118. Hualan Bio Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Hualan Bio Plasma Protein Therapeutics Product Portfolio Table 120. Hualan Bio Recent Development Table 121. Kamada Company Information Table 122. Kamada Business Overview Table 123. Kamada Plasma Protein Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. Kamada Plasma Protein Therapeutics Product Portfolio Table 125. Kamada Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Plasma Protein Therapeutics Distributors List Table 129. Plasma Protein Therapeutics Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Plasma Protein Therapeutics Product Image Figure 2. Global Plasma Protein Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Plasma Protein Therapeutics Sales (2021-2032) & (K Units) Figure 5. Global Plasma Protein Therapeutics Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Plasma Protein Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Coagulation Factor Image Figure 10. Immune Globulin Image Figure 11. Albumin Image Figure 12. Others Image Figure 13. Global Plasma Protein Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Plasma Protein Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Plasma Protein Therapeutics Sales Volume Share by Type (2021-2032) Figure 16. Global Plasma Protein Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Plasma Protein Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Plasma Protein Therapeutics Sales Value Share by Type (2021-2032) Figure 19. Hemophilia Image Figure 20. PID Image Figure 21. Others Image Figure 22. Global Plasma Protein Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Plasma Protein Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Plasma Protein Therapeutics Sales Volume Share by Application (2021-2032) Figure 25. Global Plasma Protein Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Plasma Protein Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Plasma Protein Therapeutics Sales Value Share by Application (2021-2032) Figure 28. Global Plasma Protein Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Plasma Protein Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Plasma Protein Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Plasma Protein Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Plasma Protein Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Plasma Protein Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Plasma Protein Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Plasma Protein Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Plasma Protein Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Plasma Protein Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Plasma Protein Therapeutics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Plasma Protein Therapeutics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Coagulation Factor
  • Immune Globulin
  • Albumin
  • Others
Applications
  • Hemophilia
  • PID
  • Others
Companies covered
  • Shire (Baxalta)
  • CSL
  • Grifols
  • Octapharma
  • Kedrion
  • LFB Group
  • Biotest
  • BPL
  • RAAS
  • CBPO
  • Hualan Bio
  • Kamada

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Plasma Protein Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Plasma Protein Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Plasma Protein Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Plasma Protein Therapeutics Market Dynamics
  1. 2.1 Plasma Protein Therapeutics Industry Trends
  2. 2.2 Plasma Protein Therapeutics Industry Drivers
  3. 2.3 Plasma Protein Therapeutics Industry Opportunities and Challenges
  4. 2.4 Plasma Protein Therapeutics Industry Restraints
3 Plasma Protein Therapeutics Market by Company
  1. 3.1 Global Plasma Protein Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Plasma Protein Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Plasma Protein Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Plasma Protein Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Plasma Protein Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Plasma Protein Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Plasma Protein Therapeutics Company Product Type and Application
  8. 3.8 Global Plasma Protein Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Plasma Protein Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Plasma Protein Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Plasma Protein Therapeutics Market by Type
  1. 4.1 Plasma Protein Therapeutics Type Introduction
  2. 4.1.1 Coagulation Factor
  3. 4.1.2 Immune Globulin
  4. 4.1.3 Albumin
  5. 4.1.4 Others
  6. 4.2 Global Plasma Protein Therapeutics Sales Volume by Type
  7. 4.2.1 Global Plasma Protein Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Plasma Protein Therapeutics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Plasma Protein Therapeutics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Plasma Protein Therapeutics Sales Value by Type
  11. 4.3.1 Global Plasma Protein Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Plasma Protein Therapeutics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Plasma Protein Therapeutics Sales Value Share by Type (2021-2032)
5 Plasma Protein Therapeutics Market by Application
  1. 5.1 Plasma Protein Therapeutics Application Introduction
  2. 5.1.1 Hemophilia
  3. 5.1.2 PID
  4. 5.1.3 Others
  5. 5.2 Global Plasma Protein Therapeutics Sales Volume by Application
  6. 5.2.1 Global Plasma Protein Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Plasma Protein Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Plasma Protein Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Plasma Protein Therapeutics Sales Value by Application
  10. 5.3.1 Global Plasma Protein Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Plasma Protein Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Plasma Protein Therapeutics Sales Value Share by Application (2021-2032)
6 Plasma Protein Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Plasma Protein Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Plasma Protein Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Plasma Protein Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Plasma Protein Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Plasma Protein Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Plasma Protein Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Plasma Protein Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Plasma Protein Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Plasma Protein Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Plasma Protein Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Plasma Protein Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Plasma Protein Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Plasma Protein Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Plasma Protein Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Plasma Protein Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Plasma Protein Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Plasma Protein Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Plasma Protein Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Plasma Protein Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Plasma Protein Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Plasma Protein Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Plasma Protein Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Plasma Protein Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Plasma Protein Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Plasma Protein Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Plasma Protein Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Plasma Protein Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Plasma Protein Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Plasma Protein Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Plasma Protein Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Plasma Protein Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shire (Baxalta)
  2. 8.1.1 Shire (Baxalta) Company Information
  3. 8.1.2 Shire (Baxalta) Business Overview
  4. 8.1.3 Shire (Baxalta) Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shire (Baxalta) Plasma Protein Therapeutics Product Portfolio
  6. 8.1.5 Shire (Baxalta) Recent Developments
  7. 8.2 CSL
  8. 8.2.1 CSL Company Information
  9. 8.2.2 CSL Business Overview
  10. 8.2.3 CSL Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Plasma Protein Therapeutics Product Portfolio
  12. 8.2.5 CSL Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Plasma Protein Therapeutics Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 Octapharma
  20. 8.4.1 Octapharma Company Information
  21. 8.4.2 Octapharma Business Overview
  22. 8.4.3 Octapharma Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Octapharma Plasma Protein Therapeutics Product Portfolio
  24. 8.4.5 Octapharma Recent Developments
  25. 8.5 Kedrion
  26. 8.5.1 Kedrion Company Information
  27. 8.5.2 Kedrion Business Overview
  28. 8.5.3 Kedrion Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kedrion Plasma Protein Therapeutics Product Portfolio
  30. 8.5.5 Kedrion Recent Developments
  31. 8.6 LFB Group
  32. 8.6.1 LFB Group Company Information
  33. 8.6.2 LFB Group Business Overview
  34. 8.6.3 LFB Group Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 LFB Group Plasma Protein Therapeutics Product Portfolio
  36. 8.6.5 LFB Group Recent Developments
  37. 8.7 Biotest
  38. 8.7.1 Biotest Company Information
  39. 8.7.2 Biotest Business Overview
  40. 8.7.3 Biotest Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biotest Plasma Protein Therapeutics Product Portfolio
  42. 8.7.5 Biotest Recent Developments
  43. 8.8 BPL
  44. 8.8.1 BPL Company Information
  45. 8.8.2 BPL Business Overview
  46. 8.8.3 BPL Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 BPL Plasma Protein Therapeutics Product Portfolio
  48. 8.8.5 BPL Recent Developments
  49. 8.9 RAAS
  50. 8.9.1 RAAS Company Information
  51. 8.9.2 RAAS Business Overview
  52. 8.9.3 RAAS Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 RAAS Plasma Protein Therapeutics Product Portfolio
  54. 8.9.5 RAAS Recent Developments
  55. 8.10 CBPO
  56. 8.10.1 CBPO Company Information
  57. 8.10.2 CBPO Business Overview
  58. 8.10.3 CBPO Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CBPO Plasma Protein Therapeutics Product Portfolio
  60. 8.10.5 CBPO Recent Developments
  61. 8.11 Hualan Bio
  62. 8.11.1 Hualan Bio Company Information
  63. 8.11.2 Hualan Bio Business Overview
  64. 8.11.3 Hualan Bio Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hualan Bio Plasma Protein Therapeutics Product Portfolio
  66. 8.11.5 Hualan Bio Recent Developments
  67. 8.12 Kamada
  68. 8.12.1 Kamada Company Information
  69. 8.12.2 Kamada Business Overview
  70. 8.12.3 Kamada Plasma Protein Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Kamada Plasma Protein Therapeutics Product Portfolio
  72. 8.12.5 Kamada Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Plasma Protein Therapeutics Value Chain Analysis
  2. 9.1.1 Plasma Protein Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Plasma Protein Therapeutics Sales Mode & Process
  6. 9.2 Plasma Protein Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Plasma Protein Therapeutics Distributors
  9. 9.2.3 Plasma Protein Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst